Treatment Advances & Awareness

Clinical Practice Guidelines

Guidelines for the Treatment of Chronic Hepatitis
(Includes 3 Systematic Reviews)
Released January 2017

Global Outreach & Engagement

Offered International Travel Awards

Exhibited at APASL, EASL and AMH Annual Meetings

Jointly provided global programs with AMH, APASL, ALEH, EASL and SASLT

Provided Joint Symposium with EASL and Global Forum at The Liver Meeting® 2017

Provided Sponsorship for the following programs: Gordon Research Conference; Network of Minority Health Research Investigators 15th Anniversary Annual Meeting; International HBV Meeting; 24th Annual International HCV Conference; Hepatobiliary Cancers: Pathobiology and Translational Advances; World Hepatitis Summit

Endorsed programs of: TASL; FDA/CPATH; Chinese Society of Hepatology; INASL; Hellenic Association for the Study of the Liver
Organizational Health

AASLD Membership Growth

- **32%**
  - Amount AASLD Membership has grown since 2012

- **61**
  - New AASLD Fellows (562 Total)

Ensuring the Future of Hepatology

- **240**
  - Number of Matches in the New Mentorship Program

- **29**
  - New Emerging Liver Scholars (166 since 2012)

AASLD Membership Growth

![Membership Growth Chart]

*This reflects a change in the membership year to July 1 – June 30

---

**Actual Years:**
- 2011: As of 10/22/11
- 2012: As of 1/3/13
- 2013: As of 1/3/14
- 2014: As of 1/5/15
- 2015: As of 12/14/15

*Discontinued 2013

---

**Number of Matches in the New Mentorship Program:**

- **240**

---

**New Emerging Liver Scholars (166 since 2012):**

- **29**

---

**AASLD Membership Growth:**

- **32%**
  - Amount AASLD Membership has grown since 2012

---

**Ensuring the Future of Hepatology:**

- **240**
  - Number of Matches in the New Mentorship Program

- **29**
  - New Emerging Liver Scholars (166 since 2012)

---

**AASLD Membership Growth Chart:**

- 2011: 3597
- 2012: 3683
- 2013: 4129
- 2014: 4731
- 2015: 4978
- 2016: 5313
- 2017*: 4733

---

**Corporate Affiliate**
**Emeritus**
**Associate**
**International Trainee**
**Trainee**
**International Fellow**
**Fellow**
**International**
**Regular**

---

*This reflects a change in the membership year to July 1 – June 30*
FY2017 Combined Financial Position

- Assets: $60M
- Liabilities: $11M
- Net Assets: $49M

- Foundation
  - Permanently Restricted: $4,061,850
  - Temporarily Restricted: $4,942,921
  - Unrestricted Board Designated: $7,231,413
  - Unrestricted Undesignated: $32,731,794

- AASLD
  - Net Assets: $36M

FY2017 Combined Net Assets

- Permanently Restricted: 8%
- Temporarily Restricted: 10%
- Unrestricted Board Designated: 15%
- Unrestricted Undesignated: 67%
FY2017 Combined Revenue & Expenses

<table>
<thead>
<tr>
<th>Revenue</th>
<th>$17,627,832</th>
</tr>
</thead>
<tbody>
<tr>
<td>Income from Investments</td>
<td>$4,951,657</td>
</tr>
<tr>
<td>Expenses</td>
<td>-$18,535,802</td>
</tr>
<tr>
<td><strong>Surplus</strong></td>
<td><strong>$4,043,687</strong></td>
</tr>
</tbody>
</table>

For full financial statements refer to aasld.org
AASLD & AASLD Foundation spends 85% on Programs service functions and 15% on leadership, administration and fundraising.
In Remembrance

John A. Balint, MD
Bennett L. Blitzer, MD
Lawrence Lumeng, MD
John F. Mullane, MD, PhD
Ralph M. Myerson, MD
Irvin H. Strub, MD
Thomas E. Starzl, MD, PhD, FAASLD
Juan Rodés, MD
Lina Popper

Michael W Fried, MD, FAASLD
University of North Carolina at Chapel Hill
Chapel Hill, NC

Arun J. Sanyal, MD, FAASLD
Virginia Commonwealth University
Richmond, VA
AASLD is the professional home for the innovators, educators, and clinicians in hepatology.